

	C7	IC(Δ)	P-val	FDR
	-0.762(0.015)	6.55e-05	3.10e-04	
	-0.752(0.017)	6.55e-05	3.10e-04	
	-0.742(0.022)	6.55e-05	3.10e-04	
	-0.741(0.014)	6.55e-05	3.10e-04	
	-0.737(0.026)	6.55e-05	3.10e-04	
	-0.711(0.028)	6.55e-05	3.10e-04	
	-0.697(0.009)	6.55e-05	3.10e-04	
	-0.695(0.015)	6.55e-05	3.10e-04	
	-0.693(0.010)	6.55e-05	3.10e-04	
	-0.672(0.028)	6.55e-05	3.10e-04	
	-0.671(0.009)	6.55e-05	3.10e-04	
	-0.665(0.024)	6.55e-05	3.10e-04	
	-0.663(0.028)	6.55e-05	3.10e-04	
	-0.659(0.020)	6.55e-05	3.10e-04	
	-0.658(0.014)	6.55e-05	3.10e-04	
	-0.657(0.018)	6.55e-05	3.10e-04	
	-0.655(0.002)	6.55e-05	3.10e-04	
	-0.654(0.018)	6.55e-05	3.10e-04	
	-0.646(0.029)	6.55e-05	3.10e-04	
	-0.638(0.012)	6.55e-05	3.10e-04	
	0.730(0.008)	6.55e-05	1.29e-04	
	0.731(0.021)	6.55e-05	1.29e-04	
	0.731(0.028)	6.55e-05	1.29e-04	
	0.734(0.004)	6.55e-05	1.29e-04	
	0.736(0.013)	6.55e-05	1.29e-04	
	0.738(0.016)	6.55e-05	1.29e-04	
	0.744(0.022)	6.55e-05	1.29e-04	
	0.748(0.017)	6.55e-05	1.29e-04	
	0.753(0.019)	6.55e-05	1.29e-04	
	0.755(0.016)	6.55e-05	1.29e-04	
	0.759(0.010)	6.55e-05	1.29e-04	
	0.759(0.021)	6.55e-05	1.29e-04	
	0.763(0.027)	6.55e-05	1.29e-04	
	0.765(0.017)	6.55e-05	1.29e-04	
	0.771(0.011)	6.55e-05	1.29e-04	
	0.774(0.020)	6.55e-05	1.29e-04	
	0.779(0.016)	6.55e-05	1.29e-04	
	0.782(0.019)	6.55e-05	1.29e-04	
	0.783(0.034)	6.55e-05	1.29e-04	
	0.794(0.017)	6.55e-05	1.29e-04	

C7 vs Pathway Expression

C7

SENES\_HDAC2\_TARGETS\_UP

SENES\_HDAC1\_TARGETS\_UP

BROWNE\_HCMV\_INFECTION\_2HR\_DN

XU\_HGF\_SIGNALING\_NOT\_VIA\_AKT1\_6HR

SENES\_HDAC1\_AND\_HDAC2\_TARGETS\_UP

AMIT\_EGF\_RESPONSE\_480\_HELA

BMI1\_DN\_MEL18\_DN.V1

AMIT\_EGF\_RESPONSE\_480\_MCF10A

MEL18\_DN.V1

KIM\_WT1\_TARGETS\_12HR\_DN

AMIT\_EGF\_RESPONSE\_240\_HELA

HUANG\_DASATINIB\_RESISTANCE

XU\_HGF\_SIGNALING\_NOT\_VIA\_AKT1\_48HR\_UP

HUANG\_DASATINIB\_RESISTANCE\_UP

KRAS.DF.V1\_UP

PEDERSEN\_TARGETS\_OF\_611CTF\_ISOFORM\_OF\_ERBB2

NIELSEN\_LEIOMYOSARCOMA

FULCHER\_INFLAMMATORY\_RESPONSE\_LLECTIN\_VS\_LPS\_UP

BMI1\_DN.V1

ZHANG\_ANTIVIRAL\_RESPONSE\_TO\_RIBAVIRIN\_DN

BROWNE\_HCMV\_INFECTION\_10HR

GUENTHER\_GROWTH\_SPHERICAL\_VS\_ADHERENT

LEE\_LIVER\_CANCER\_SURVIVAL

BROWNE\_HCMV\_INFECTION\_8HR

RICKMAN\_TUMOR\_DIFFERENTIATED\_WELL\_VS\_POORLY

ESC\_V6.5\_UP\_EARLY.V1

GHO\_ATF5\_TARGETS

PETROVA\_PROX1\_TARGETS

BROWNE\_HCMV\_INFECTION\_14HR

RIGGI EWING\_SARCOMA\_PROGENITOR

RICKMAN\_TUMOR\_DIFFERENTIATED\_WELL\_VS\_MODERATELY

Weinmann\_Adaptation\_to\_hypoxia

BROWNE\_HCMV\_INFECTION\_20HR

KUNINGER\_IGF1\_VS\_PDGFB\_TARGETS

SRC\_UP.V1

OSADA\_ASCL1\_TARGETS

CHARAFE\_BREAST\_CANCER\_LUMINAL\_VS\_BASAL

Petrova\_Endothelium\_lymphatic\_vs\_blood

Kobayashi\_EGFR\_SIGNALING\_6HR

REN\_ALVEOLAR\_RHABDOMYOSARCOMA